{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T06:52:17Z","timestamp":1792479137609,"version":"4.5.0"},"reference-count":112,"publisher":"IMR Press","issue":"10","license":[{"start":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T00:00:00Z","timestamp":1760918400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rev. Cardiovasc. Med."],"abstract":"<jats:p>Cardiac amyloidosis (CA) has emerged from the margins of cardiology to the forefront of research and practice on heart failure. Once regarded as rare and elusive, CA is now recognized as a significant cause of heart failure with preserved ejection fraction (HFpEF), arrhythmias, and valvular disease, especially in older patients. CA is characterized by extracellular deposition of misfolded protein fibrils, which infiltrate the myocardium and disrupt the structural and electrical integrity. Although CA can stem from multiple amyloid types, transthyretin amyloidosis (ATTR) and light-chain (AL) amyloidosis are the predominant subtypes with cardiac involvement, each carrying distinct implications for prognosis and therapy. This review explores CA as a clinical reality often obscured by more common cardiovascular syndromes. Moreover, this review focuses on the varied presentations of CA in real-world practice, how the condition overlaps with HFpEF, the subtle clues for CA amid common valvular disorders, and the complex rhythm manifestations of the condition. Particular attention is given to thromboembolic risk, microvascular dysfunction, and the evolving paradigm of preclinical or asymptomatic amyloidosis management. Furthermore, this review addresses contemporary challenges such as financial toxicity and the cost-effectiveness of screening, emphasizing the benefits of early detection and therapy. The paper also discusses risk stratification and staging, drawing from validated models to guide both prognosis and treatment decisions, and the role of histopathological characterization. Thus, this review underscores the importance of timely recognition and tailored intervention in transforming CA from a terminal diagnosis into a manageable chronic condition.<\/jats:p>","DOI":"10.31083\/rcm42514","type":"journal-article","created":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T12:38:13Z","timestamp":1762519093000},"source":"Crossref","is-referenced-by-count":5,"title":["Cardiac Amyloidosis in the Real World: Clinical Presentations, Disease Overlap, and Therapeutic Imperatives"],"prefix":"10.31083","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4318-8843","authenticated-orcid":true,"given":"Karim","family":"Ali","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Hennepin County Medical Center, Minneapolis, MN 55415, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0388-3174","authenticated-orcid":true,"given":"Ahmed E.","family":"Ali","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Crestwood Medical Center, Huntsville, AL 35801, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6494-388X","authenticated-orcid":true,"given":"Ahmad","family":"Alayyat","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Hamilton Medical Center, Dalton, GA 30720, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6501-6845","authenticated-orcid":true,"given":"Mohamed K.","family":"Awad","sequence":"first","affiliation":[{"name":"Department of Critical Care, Faculty of Medicine, Ain Shams University, 11646 Cairo, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3295-2484","authenticated-orcid":true,"given":"Hussain","family":"Majeed","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Northeast Georgia Medical Center, Gainesville, GA 30501, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed S.","family":"Amer","sequence":"first","affiliation":[{"name":"Department of Cardiology, El Mansoura International Hospital, 35516 Mansoura, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9041-1844","authenticated-orcid":true,"given":"Ahmed Sami","family":"Abuzaid","sequence":"first","affiliation":[{"name":"Alaska Heart and Vascular Institute, University of Alaska, Anchorage, AK 99571, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"16242","published-online":{"date-parts":[[2025,10,20]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Xin Y, Hu W, Chen X, Hu J, Sun Y, Zhao Y. Prognostic impact of light-chain and transthyretin-related categories in cardiac amyloidosis: A systematic review and meta-analysis. Hellenic Journal of Cardiology: HJC = Hellenike Kardiologike Epitheorese. 2019; 60: 375\u2013383.","DOI":"10.1016\/j.hjc.2019.01.015"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Fontana M, Ioannou A, Cuddy S, Dorbala S, Masri A, Moon JC, et al. The Last Decade in Cardiac Amyloidosis: Advances in Understanding Pathophysiology, Diagnosis and Quantification, Prognosis, Treatment Strategies, and Monitoring Response. JACC. Cardiovascular Imaging. 2025; 18: 478\u2013499.","DOI":"10.1016\/j.jcmg.2024.10.011"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Yamamoto H, Yokochi T. Transthyretin cardiac amyloidosis: an update on diagnosis and treatment. ESC Heart Failure. 2019; 6: 1128\u20131139.","DOI":"10.1002\/ehf2.12518"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Merlini G, Dispenzieri A, Sanchorawala V, Sch\u00f6nland SO, Palladini G, Hawkins PN, et al. Systemic immunoglobulin light chain amyloidosis. Nature Reviews. Disease Primers. 2018; 4: 38.","DOI":"10.1038\/s41572-018-0034-3"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Grogan M, Scott CG, Kyle RA, Zeldenrust SR, Gertz MA, Lin G, et al. Natural History of Wild-Type Transthyretin Cardiac Amyloidosis and Risk Stratification Using a Novel Staging System. Journal of the American College of Cardiology. 2016; 68: 1014\u20131020.","DOI":"10.1016\/j.jacc.2016.06.033"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Gillmore JD, Damy T, Fontana M, Hutchinson M, Lachmann HJ, Martinez-Naharro A, et al. A new staging system for cardiac transthyretin amyloidosis. European Heart Journal. 2018; 39: 2799\u20132806.","DOI":"10.1093\/eurheartj\/ehx589"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Cheng RK, Levy WC, Vasbinder A, Teruya S, De Los Santos J, Leedy D, et al. Diuretic Dose and NYHA Functional Class Are Independent Predictors of Mortality in Patients With Transthyretin Cardiac Amyloidosis. JACC. CardioOncology. 2020; 2: 414\u2013424.","DOI":"10.1016\/j.jaccao.2020.06.007"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Grasso M, Cavaliere C, Vilardo V, Tagliani M, Di Toro A, Urtis M, et al. Present and future of endomyocardial biopsy in cardiac amyloidosis. European Heart Journal Supplements: Journal of the European Society of Cardiology. 2025; 27: iii7\u2013iii12.","DOI":"10.1093\/eurheartjsupp\/suaf036"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Anderson L, Pennell D. The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology. European Heart Journal. 2008; 29: 1696; author reply 1696\u20137.","DOI":"10.1093\/eurheartj\/ehn189"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Dorbala S. Expanding indications for non-biopsy diagnosis of transthyretin amyloid cardiomyopathy. European Heart Journal. 2023; 44: 2199\u20132201.","DOI":"10.1093\/eurheartj\/ehad281"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Briasoulis A, Bampatsias D, Papamichail A, Kuno T, Skoularigis J, Xanthopoulos A, et al. Invasive and Non-Invasive Diagnostic Pathways in the Diagnosis of Cardiac Amyloidosis. Journal of Cardiovascular Development and Disease. 2023; 10: 256.","DOI":"10.3390\/jcdd10060256"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Westin O, Fosb\u00f8l EL, Maurer MS, Leicht BP, Hasbak P, Mylin AK, et al. Screening for Cardiac Amyloidosis 5 to 15 Years After Surgery for Bilateral Carpal Tunnel Syndrome. Journal of the American College of Cardiology. 2022; 80: 967\u2013977.","DOI":"10.1016\/j.jacc.2022.06.026"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Gonz\u00e1lez-L\u00f3pez E, Gallego-Delgado M, Guzzo-Merello G, de Haro-Del Moral FJ, Cobo-Marcos M, Robles C, et al. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. European Heart Journal. 2015; 36: 2585\u20132594.","DOI":"10.1093\/eurheartj\/ehv338"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Jaiswal V, Agrawal V, Khulbe Y, Hanif M, Huang H, Hameed M, et al. Cardiac amyloidosis and aortic stenosis: a state-of-the-art review. European Heart Journal Open. 2023; 3: oead106.","DOI":"10.1093\/ehjopen\/oead106"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Nitsche C, Scully PR, Patel KP, Kammerlander AA, Koschutnik M, Dona C, et al. Prevalence and Outcomes of Concomitant Aortic Stenosis and Cardiac Amyloidosis. Journal of the American College of Cardiology. 2021; 77: 128\u2013139.","DOI":"10.1016\/j.jacc.2020.11.006"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Caponetti AG, Accietto A, Saturi G, Ponziani A, Sguazzotti M, Massa P, et al. Screening approaches to cardiac amyloidosis in different clinical settings: Current practice and future perspectives. Frontiers in Cardiovascular Medicine. 2023; 10: 1146725.","DOI":"10.3389\/fcvm.2023.1146725"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A, et al. Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis. Circulation. 2016; 133: 2404\u20132412.","DOI":"10.1161\/CIRCULATIONAHA.116.021612"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Maurer MS, Elliott P, Comenzo R, Semigran M, Rapezzi C. Addressing Common Questions Encountered in the Diagnosis and Management of Cardiac Amyloidosis. Circulation. 2017; 135: 1357\u20131377.","DOI":"10.1161\/CIRCULATIONAHA.116.024438"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Maggialetti N, Torrente A, Lorusso G, Villanova I, Ficco M, Gravina M, et al. Role of Cardiovascular Magnetic Resonance in Cardiac Amyloidosis: A Narrative Review. Journal of Personalized Medicine. 2024; 14: 407.","DOI":"10.3390\/jpm14040407"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"M\u00fcller ML, Spethmann S, Messroghli D, Brand A, Mattig I, Hahn K, et al. Accuracy of Established Prognostic Staging Systems for Cardiac Transthyretin Amyloidosis in the Tafamidis Era. JACC. Advances. 2025; 4: 101568.","DOI":"10.1016\/j.jacadv.2024.101568"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Garcia-Pavia P, Bengel F, Brito D, Damy T, Duca F, Dorbala S, et al. Expert consensus on the monitoring of transthyretin amyloid cardiomyopathy. European Journal of Heart Failure. 2021; 23: 895\u2013905.","DOI":"10.1002\/ejhf.2198"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"De Andr\u00e9s-Cardelle F, Barge-Caballero G, L\u00f3pez-P\u00e9rez M, L\u00f3pez-L\u00f3pez A, Gonz\u00e1lez-Babarro E, Guti\u00e9rrez-Feijoo M, et al. Usefulness of the Columbia score for predicting outcomes in patients with transthyretin amyloid cardiomyopathy. Analysis of the Galician registry of cardiac amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis. 2025; 32: 145\u2013153.","DOI":"10.1080\/13506129.2025.2453231"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"Casta\u00f1o A, Narotsky DL, Hamid N, Khalique OK, Morgenstern R, DeLuca A, et al. Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement. European Heart Journal. 2017; 38: 2879\u20132887.","DOI":"10.1093\/eurheartj\/ehx350"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Jaiswal V, Ang SP, Chia JE, Abdelazem EM, Jaiswal A, Biswas M, et al. Echocardiographic predictors of presence of cardiac amyloidosis in aortic stenosis. European Heart Journal. Cardiovascular Imaging. 2022; 23: 1290\u20131301.","DOI":"10.1093\/ehjci\/jeac146"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"Cavalcante JL, Rijal S, Abdelkarim I, Althouse AD, Sharbaugh MS, Fridman Y, et al. Cardiac amyloidosis is prevalent in older patients with aortic stenosis and carries worse prognosis. Journal of Cardiovascular Magnetic Resonance: Official Journal of the Society for Cardiovascular Magnetic Resonance. 2017; 19: 98.","DOI":"10.1186\/s12968-017-0415-x"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Kristen AV, Schnabel PA, Winter B, Helmke BM, Longerich T, Hardt S, et al. High prevalence of amyloid in 150 surgically removed heart valves\u2013a comparison of histological and clinical data reveals a correlation to atheroinflammatory conditions. Cardiovascular Pathology: the Official Journal of the Society for Cardiovascular Pathology. 2010; 19: 228\u2013235.","DOI":"10.1016\/j.carpath.2009.04.005"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"Ternacle J, Krapf L, Mohty D, Magne J, Nguyen A, Galat A, et al. Aortic Stenosis and Cardiac Amyloidosis: JACC Review Topic of the Week. Journal of the American College of Cardiology. 2019; 74: 2638\u20132651.","DOI":"10.1016\/j.jacc.2019.09.056"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, et al. Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. The New England Journal of Medicine. 2018; 379: 1007\u20131016.","DOI":"10.1056\/NEJMoa1805689"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"Galat A, Guellich A, Bodez D, Slama M, Dijos M, Zeitoun DM, et al. Aortic stenosis and transthyretin cardiac amyloidosis: the chicken or the egg? European Heart Journal. 2016; 37: 3525\u20133531.","DOI":"10.1093\/eurheartj\/ehw033"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"Cannata F, Chiarito M, Pinto G, Villaschi A, Sanz-S\u00e1nchez J, Fazzari F, et al. Transcatheter aortic valve replacement in aortic stenosis and cardiac amyloidosis: a systematic review and meta-analysis. ESC Heart Failure. 2022; 9: 3188\u20133197.","DOI":"10.1002\/ehf2.13876"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"Minga I, Kwak E, Hussain K, Wathen L, Gaznabi S, Singh L, et al. Prevalence of valvular heart disease in cardiac amyloidosis and impact on survival. Current Problems in Cardiology. 2024; 49: 102417.","DOI":"10.1016\/j.cpcardiol.2024.102417"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"Tomasoni D, Aimo A, Porcari A, Bonfioli GB, Castiglione V, Saro R, et al. Prevalence and clinical outcomes of isolated or combined moderate to severe mitral and tricuspid regurgitation in patients with cardiac amyloidosis. European Heart Journal. Cardiovascular Imaging. 2024; 25: 1007\u20131017.","DOI":"10.1093\/ehjci\/jeae060"},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"Chacko L, Karia N, Venneri L, Bandera F, Passo BD, Buonamici L, et al. Progression of echocardiographic parameters and prognosis in transthyretin cardiac amyloidosis. European Journal of Heart Failure. 2022; 24: 1700\u20131712.","DOI":"10.1002\/ejhf.2606"},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"Duca F, Kronberger C, Willixhofer R, Bartko PE, Bergler-Klein J, Nitsche C. Cardiac Amyloidosis and Valvular Heart Disease. Journal of Clinical Medicine. 2023; 13: 221.","DOI":"10.3390\/jcm13010221"},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"Fagot J, Lavie-Badie Y, Blanchard V, Fournier P, Galinier M, Carri\u00e9 D, et al. Impact of tricuspid regurgitation on survival in patients with cardiac amyloidosis. ESC Heart Failure. 2021; 8: 438\u2013446.","DOI":"10.1002\/ehf2.13093"},{"key":"ref36","doi-asserted-by":"publisher","unstructured":"Masugata H, Mizushige K, Senda S, Kinoshita A, Nozaki S, Matsuo H, et al. Physical properties of the mitral valve tissue assessed by tissue sound speed in cardiac amyloidosis: relationship to the severity of mitral regurgitation. Ultrasound in Medicine & Biology. 2000; 26: 1191\u20131198.","DOI":"10.1016\/s0301-5629(00)00259-3"},{"key":"ref37","doi-asserted-by":"publisher","unstructured":"Aimo A, Camerini L, Fabiani I, Morfino P, Panichella G, Barison A, et al. Valvular heart disease in patients with cardiac amyloidosis. Heart Failure Reviews. 2024; 29: 65\u201377.","DOI":"10.1007\/s10741-023-10350-1"},{"key":"ref38","doi-asserted-by":"publisher","unstructured":"Nishi H, Mitsuno M, Ryomoto M, Miyamoto Y. Severe mitral regurgitation due to cardiac amyloidosis\u2013a rare reason for ruptured chordae. Interactive Cardiovascular and Thoracic Surgery. 2008; 7: 1199\u20131200.","DOI":"10.1510\/icvts.2008.187179"},{"key":"ref39","doi-asserted-by":"publisher","unstructured":"Don\u00e0 C, Nitsche C, Koschutnik M, Heitzinger G, Mascherbauer K, Kammerlander AA, et al. Unveiling Cardiac Amyloidosis, its Characteristics, and Outcomes Among Patients With MR Undergoing Transcatheter Edge-to-Edge MV Repair. JACC. Cardiovascular Interventions. 2022; 15: 1748\u20131758.","DOI":"10.1016\/j.jcin.2022.06.009"},{"key":"ref40","doi-asserted-by":"publisher","unstructured":"Chacko L, Martone R, Bandera F, Lane T, Martinez-Naharro A, Boldrini M, et al. Echocardiographic phenotype and prognosis in transthyretin cardiac amyloidosis. European Heart Journal. 2020; 41: 1439\u20131447.","DOI":"10.1093\/eurheartj\/ehz905"},{"key":"ref41","doi-asserted-by":"publisher","unstructured":"Volz MJ, Pleger ST, Weber A, Geis NA, Hamed S, Mereles D, et al. Initial experience with percutaneous mitral valve repair in patients with cardiac amyloidosis. European Journal of Clinical Investigation. 2021; 51: e13473.","DOI":"10.1111\/eci.13473"},{"key":"ref42","doi-asserted-by":"publisher","unstructured":"Hoerbrand IA, Volz MJ, Aus dem Siepen F, Aurich M, Schlegel P, Geis NA, et al. Initial experience with transcatheter tricuspid valve repair in patients with cardiac amyloidosis. ESC Heart Failure. 2023; 10: 1003\u20131012.","DOI":"10.1002\/ehf2.14262"},{"key":"ref43","doi-asserted-by":"publisher","unstructured":"Kwak S, Lim S, Kim YJ, Kim HK. Isolated severe mitral stenosis as an uncommon manifestation of cardiac amyloidosis. Journal of Cardiovascular Imaging. 2024; 32: 17.","DOI":"10.1186\/s44348-024-00013-6"},{"key":"ref44","doi-asserted-by":"publisher","unstructured":"Randhawa VK, Vakamudi S, Phelan DM, Samaras CJ, McKenney JK, Hanna M, et al. Mitral and tricuspid stenosis caused by light chain cardiac amyloid deposition. ESC Heart Failure. 2020; 7: 1130\u20131135.","DOI":"10.1002\/ehf2.12668"},{"key":"ref45","doi-asserted-by":"publisher","unstructured":"Frumkin D, Taube ET, Stangl K, Knebel F. Rapid progression of aortic and mitral stenosis in a patient with AA amyloidosis: a case report. European Heart Journal. Case Reports. 2019; 3: ytz051.","DOI":"10.1093\/ehjcr\/ytz051"},{"key":"ref46","doi-asserted-by":"publisher","unstructured":"Mints YY, Doros G, Berk JL, Connors LH, Ruberg FL. Features of atrial fibrillation in wild-type transthyretin cardiac amyloidosis: a systematic review and clinical experience. ESC Heart Failure. 2018; 5: 772\u2013779.","DOI":"10.1002\/ehf2.12308"},{"key":"ref47","doi-asserted-by":"publisher","unstructured":"Staerk L, Sherer JA, Ko D, Benjamin EJ, Helm RH. Atrial Fibrillation: Epidemiology, Pathophysiology, and Clinical Outcomes. Circulation Research. 2017; 120: 1501\u20131517.","DOI":"10.1161\/CIRCRESAHA.117.309732"},{"key":"ref48","doi-asserted-by":"publisher","unstructured":"Wang TJ, Larson MG, Levy D, Vasan RS, Leip EP, Wolf PA, et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study. Circulation. 2003; 107: 2920\u20132925.","DOI":"10.1161\/01.CIR.0000072767.89944.6E"},{"key":"ref49","doi-asserted-by":"publisher","unstructured":"Giancaterino S, Urey MA, Darden D, Hsu JC. Management of Arrhythmias in Cardiac Amyloidosis. JACC. Clinical Electrophysiology. 2020; 6: 351\u2013361.","DOI":"10.1016\/j.jacep.2020.01.004"},{"key":"ref50","doi-asserted-by":"publisher","unstructured":"Writing Committee, Kittleson MM, Ruberg FL, Ambardekar AV, Brannagan TH, Cheng RK, et al. 2023 ACC Expert Consensus Decision Pathway on Comprehensive Multidisciplinary Care for the Patient With Cardiac Amyloidosis: A Report of the American College of Cardiology Solution Set Oversight Committee. Journal of the American College of Cardiology. 2023; 81: 1076\u20131126.","DOI":"10.1016\/j.jacc.2022.11.022"},{"key":"ref51","doi-asserted-by":"publisher","unstructured":"Bukhari S, Khan SZ, Bashir Z. Atrial Fibrillation, Thromboembolic Risk, and Anticoagulation in Cardiac Amyloidosis: A Review. Journal of Cardiac Failure. 2023; 29: 76\u201386.","DOI":"10.1016\/j.cardfail.2022.08.008"},{"key":"ref52","doi-asserted-by":"publisher","unstructured":"Lee SR, Choi JM. Is It Time to Expand the Indication of DOAC to Patients With Cardiac Amyloidosis and Atrial Fibrillation? International Journal of Heart Failure. 2024; 6: 44\u201345.","DOI":"10.36628\/ijhf.2024.0002"},{"key":"ref53","doi-asserted-by":"publisher","unstructured":"Nong Q, Liang S, Zhu W, Chen Y, Zhang T. Direct Oral Anticoagulants vs. Vitamin K Antagonists for Atrial Fibrillation in Cardiac Amyloidosis: A Systematic Review and Meta-analysis. Reviews in Cardiovascular Medicine. 2025; 26: 26948.","DOI":"10.31083\/RCM26948"},{"key":"ref54","doi-asserted-by":"publisher","unstructured":"Cheung CC, Roston TM, Andrade JG, Bennett MT, Davis MK. Arrhythmias in Cardiac Amyloidosis: Challenges in Risk Stratification and Treatment. The Canadian Journal of Cardiology. 2020; 36: 416\u2013423.","DOI":"10.1016\/j.cjca.2019.11.039"},{"key":"ref55","doi-asserted-by":"publisher","unstructured":"Gertz MA, Skinner M, Connors LH, Falk RH, Cohen AS, Kyle RA. Selective binding of nifedipine to amyloid fibrils. The American Journal of Cardiology. 1985; 55: 1646.","DOI":"10.1016\/0002-9149(85)90996-8"},{"key":"ref56","doi-asserted-by":"publisher","unstructured":"Rubinow A, Skinner M, Cohen AS. Digoxin sensitivity in amyloid cardiomyopathy. Circulation. 1981; 63: 1285\u20131288.","DOI":"10.1161\/01.cir.63.6.1285"},{"key":"ref57","doi-asserted-by":"publisher","unstructured":"Tan NY, Mohsin Y, Hodge DO, Lacy MQ, Packer DL, Dispenzieri A, et al. Catheter Ablation for Atrial Arrhythmias in Patients With Cardiac Amyloidosis. Journal of Cardiovascular Electrophysiology. 2016; 27: 1167\u20131173.","DOI":"10.1111\/jce.13046"},{"key":"ref58","doi-asserted-by":"publisher","unstructured":"Barbhaiya CR, Kumar S, Baldinger SH, Michaud GF, Stevenson WG, Falk R, et al. Electrophysiologic assessment of conduction abnormalities and atrial arrhythmias associated with amyloid cardiomyopathy. Heart Rhythm. 2016; 13: 383\u2013390.","DOI":"10.1016\/j.hrthm.2015.09.016"},{"key":"ref59","doi-asserted-by":"publisher","unstructured":"Donnellan E, Wazni O, Kanj M, Elshazly MB, Hussein A, Baranowski B, et al. Atrial fibrillation ablation in patients with transthyretin cardiac amyloidosis. Europace: European Pacing, Arrhythmias, and Cardiac Electrophysiology: Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology. 2020; 22: 259\u2013264.","DOI":"10.1093\/europace\/euz314"},{"key":"ref60","doi-asserted-by":"publisher","unstructured":"Dale Z, Chandrashekar P, Al-Rashdan L, Gill S, Elman M, Fischer KL, et al. Routine ambulatory heart rhythm monitoring for detection of atrial arrhythmias in transthyretin cardiac amyloidosis. International Journal of Cardiology. 2022; 358: 65\u201371.","DOI":"10.1016\/j.ijcard.2022.04.045"},{"key":"ref61","doi-asserted-by":"publisher","unstructured":"Stables RH, Ormerod OJ. Atrial thrombi occurring during sinus rhythm in cardiac amyloidosis: evidence for atrial electromechanical dissociation. Heart (British Cardiac Society). 1996; 75: 426.","DOI":"10.1136\/hrt.75.4.426-b"},{"key":"ref62","doi-asserted-by":"publisher","unstructured":"Donnellan E, Elshazly MB, Vakamudi S, Wazni OM, Cohen JA, Kanj M, et al. No Association Between CHADS-VASc Score and Left Atrial Appendage Thrombus in Patients With Transthyretin Amyloidosis. JACC. Clinical Electrophysiology. 2019; 5: 1473\u20131474.","DOI":"10.1016\/j.jacep.2019.10.013"},{"key":"ref63","doi-asserted-by":"publisher","unstructured":"El-Am EA, Dispenzieri A, Melduni RM, Ammash NM, White RD, Hodge DO, et al. Direct Current Cardioversion of Atrial Arrhythmias in Adults With Cardiac Amyloidosis. Journal of the American College of Cardiology. 2019; 73: 589\u2013597.","DOI":"10.1016\/j.jacc.2018.10.079"},{"key":"ref64","doi-asserted-by":"publisher","unstructured":"Sucker C, Hetzel GR, Grabensee B, Stockschlaeder M, Scharf RE. Amyloidosis and bleeding: pathophysiology, diagnosis, and therapy. American Journal of Kidney Diseases: the Official Journal of the National Kidney Foundation. 2006; 47: 947\u2013955.","DOI":"10.1053\/j.ajkd.2006.03.036"},{"key":"ref65","doi-asserted-by":"publisher","unstructured":"Wang XF, Li T, Yang M, Huang Y. Periorbital purpura can be the only initial symptom of primary light chain amyloidosis: A case report. World Journal of Clinical Cases. 2024; 12: 5946\u20135951.","DOI":"10.12998\/wjcc.v12.i26.5946"},{"key":"ref66","doi-asserted-by":"publisher","unstructured":"Dejhansathit S, Suvannasankha A. Acquired Factor X Deficiency in Patients With Primary Light Chain Amyloidosis. Journal of Investigative Medicine High Impact Case Reports. 2019; 7: 2324709619832332.","DOI":"10.1177\/2324709619832332"},{"key":"ref67","doi-asserted-by":"publisher","unstructured":"Manikkan AT. Factor X deficiency: an uncommon presentation of AL amyloidosis. Upsala Journal of Medical Sciences. 2012; 117: 457\u2013459.","DOI":"10.3109\/03009734.2012.690457"},{"key":"ref68","doi-asserted-by":"crossref","unstructured":"Liebman H, Chinowsky M, Valdin J, Kenoyer G, Feinstein D. Increased fibrinolysis and amyloidosis. Archives of Internal Medicine. 1983; 143: 678\u2013682.","DOI":"10.1001\/archinte.1983.00350040068009"},{"key":"ref69","doi-asserted-by":"publisher","unstructured":"Lacy SC, Kinno M, Joyce C, Yu MD. Direct Oral Anticoagulants in Patients With Cardiac Amyloidosis: A Systematic Review and Meta-Analysis. International Journal of Heart Failure. 2023; 6: 36\u201343.","DOI":"10.36628\/ijhf.2023.0031"},{"key":"ref70","doi-asserted-by":"publisher","unstructured":"Roccatello D, Fenoglio R, Sciascia S, Naretto C, Rossi D, Ferro M, et al. CD38 and Anti-CD38 Monoclonal Antibodies in AL Amyloidosis: Targeting Plasma Cells and beyond. International Journal of Molecular Sciences. 2020; 21: 4129.","DOI":"10.3390\/ijms21114129"},{"key":"ref71","doi-asserted-by":"publisher","unstructured":"Bianchi G, Zhang Y, Comenzo RL. AL Amyloidosis: Current Chemotherapy and Immune Therapy Treatment Strategies: JACC: CardioOncology State-of-the-Art Review. JACC. CardioOncology. 2021; 3: 467\u2013487.","DOI":"10.1016\/j.jaccao.2021.09.003"},{"key":"ref72","doi-asserted-by":"publisher","unstructured":"Mesquita ET, Jorge AJL, Souza CV, Junior, Andrade TRD. Cardiac Amyloidosis and its New Clinical Phenotype: Heart Failure with Preserved Ejection Fraction. Arquivos Brasileiros De Cardiologia. 2017; 109: 71\u201380.","DOI":"10.5935\/abc.20170079"},{"key":"ref73","doi-asserted-by":"publisher","unstructured":"Olivotto I, Udelson JE, Pieroni M, Rapezzi C. Genetic causes of heart failure with preserved ejection fraction: emerging pharmacological treatments. European Heart Journal. 2023; 44: 656\u2013667.","DOI":"10.1093\/eurheartj\/ehac764"},{"key":"ref74","doi-asserted-by":"publisher","unstructured":"Antonopoulos AS, Panagiotopoulos I, Kouroutzoglou A, Koutsis G, Toskas P, Lazaros G, et al. Prevalence and clinical outcomes of transthyretin amyloidosis: a systematic review and meta-analysis. European Journal of Heart Failure. 2022; 24: 1677\u20131696.","DOI":"10.1002\/ejhf.2589"},{"key":"ref75","doi-asserted-by":"publisher","unstructured":"Tanskanen M, Peuralinna T, Polvikoski T, Notkola IL, Sulkava R, Hardy J, et al. Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2-macroglobulin and tau: a population-based autopsy study. Annals of Medicine. 2008; 40: 232\u2013239.","DOI":"10.1080\/07853890701842988"},{"key":"ref76","doi-asserted-by":"publisher","unstructured":"Cipriani A, De Michieli L, Porcari A, Licchelli L, Sinigiani G, Tini G, et al. Low QRS Voltages in Cardiac Amyloidosis: Clinical Correlates and Prognostic Value. JACC. CardioOncology. 2022; 4: 458\u2013470.","DOI":"10.1016\/j.jaccao.2022.08.007"},{"key":"ref77","doi-asserted-by":"publisher","unstructured":"Argir\u00f2 A, Del Franco A, Mazzoni C, Allinovi M, Tomberli A, Tarquini R, et al. Arrhythmic Burden in Cardiac Amyloidosis: What We Know and What We Do Not. Biomedicines. 2022; 10: 2888.","DOI":"10.3390\/biomedicines10112888"},{"key":"ref78","doi-asserted-by":"publisher","unstructured":"Mesquita T, Zhang R, Cho JH, Zhang R, Lin YN, Sanchez L, et al. Mechanisms of Sinoatrial Node Dysfunction in Heart Failure With Preserved Ejection Fraction. Circulation. 2022; 145: 45\u201360.","DOI":"10.1161\/CIRCULATIONAHA.121.054976"},{"key":"ref79","doi-asserted-by":"publisher","unstructured":"Maloberti A, Ciampi C, Politi F, Fabbri S, Musca F, Giannattasio C. Cardiac amyloidosis red flags: What all the cardiologist have to know. International Journal of Cardiology. Cardiovascular Risk and Prevention. 2024; 21: 200271.","DOI":"10.1016\/j.ijcrp.2024.200271"},{"key":"ref80","doi-asserted-by":"publisher","unstructured":"Dorbala S, Vangala D, Bruyere J, Jr, Quarta C, Kruger J, Padera R, et al. Coronary microvascular dysfunction is related to abnormalities in myocardial structure and function in cardiac amyloidosis. JACC. Heart Failure. 2014; 2: 358\u2013367.","DOI":"10.1016\/j.jchf.2014.03.009"},{"key":"ref81","doi-asserted-by":"publisher","unstructured":"Kolijn D, Kov\u00e1cs \u00c1, Herwig M, L\u00f3di M, Sieme M, Alhaj A, et al. Enhanced Cardiomyocyte Function in Hypertensive Rats With Diastolic Dysfunction and Human Heart Failure Patients After Acute Treatment With Soluble Guanylyl Cyclase (sGC) Activator. Frontiers in Physiology. 2020; 11: 345.","DOI":"10.3389\/fphys.2020.00345"},{"key":"ref82","doi-asserted-by":"publisher","unstructured":"Franssen C, Chen S, Unger A, Korkmaz HI, De Keulenaer GW, Tsch\u00f6pe C, et al. Myocardial Microvascular Inflammatory Endothelial Activation in Heart Failure With Preserved Ejection Fraction. JACC. Heart Failure. 2016; 4: 312\u2013324.","DOI":"10.1016\/j.jchf.2015.10.007"},{"key":"ref83","doi-asserted-by":"publisher","unstructured":"Saito Y, Nakamura K, Ito H. Molecular Mechanisms of Cardiac Amyloidosis. International Journal of Molecular Sciences. 2021; 23: 25.","DOI":"10.3390\/ijms23010025"},{"key":"ref84","doi-asserted-by":"publisher","unstructured":"Sinha A, Rahman H, Perera D. Coronary microvascular dysfunction and heart failure with preserved ejection fraction: what are the mechanistic links? Current Opinion in Cardiology. 2023; 38: 521\u2013526.","DOI":"10.1097\/HCO.0000000000001082"},{"key":"ref85","doi-asserted-by":"publisher","unstructured":"Netti L, Ioannou A, Martinez-Naharro A, Razvi Y, Porcari A, Venneri L, et al. Microvascular obstruction in cardiac amyloidosis. European Journal of Heart Failure. 2024;  https:\/\/doi.org\/ (online ahead of print)","DOI":"10.1002\/ejhf.3481"},{"key":"ref86","doi-asserted-by":"publisher","unstructured":"Aimo A, Bonino L, Castiglione V, Musetti V, Rossetti M, Celi A, et al. Rarefaction of Blood, But Not Lymphatic Capillaries, in Patients With Cardiac Amyloidosis. JACC. CardioOncology. 2024; 6: 797\u2013799.","DOI":"10.1016\/j.jaccao.2024.07.009"},{"key":"ref87","doi-asserted-by":"publisher","unstructured":"Falk RH, Alexander KM, Liao R, Dorbala S. AL (Light-Chain) Cardiac Amyloidosis: A Review of Diagnosis and Therapy. Journal of the American College of Cardiology. 2016; 68: 1323\u20131341.","DOI":"10.1016\/j.jacc.2016.06.053"},{"key":"ref88","doi-asserted-by":"publisher","unstructured":"Nguyen HT, Nguyen CTH. Cardiac amyloidosis mimicking acute coronary syndrome: a case report and literature review. European Heart Journal. Case Reports. 2020; 4: 1\u20137.","DOI":"10.1093\/ehjcr\/ytaa325"},{"key":"ref89","doi-asserted-by":"publisher","unstructured":"Nakamura K, Yoshinaga T, Sakyu A, Matsushima A, Yonehara Y, Kojima T, et al. Genetic counselling for at-risk family members with hereditary transthyretin amyloidosis: data from a single-centre study. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis. 2024; 31: 179\u2013183.","DOI":"10.1080\/13506129.2024.2357094"},{"key":"ref90","doi-asserted-by":"publisher","unstructured":"Ueda M, Sekijima Y, Koike H, Yamashita T, Yoshinaga T, Ishii T, et al. Monitoring of asymptomatic family members at risk of hereditary transthyretin amyloidosis for early intervention with disease-modifying therapies. Journal of the Neurological Sciences. 2020; 414: 116813.","DOI":"10.1016\/j.jns.2020.116813"},{"key":"ref91","doi-asserted-by":"publisher","unstructured":"Schmidt HHJ, Barroso F, Gonz\u00e1lez-Duarte A, Concei\u00e7\u00e3o I, Obici L, Keohane D, et al. Management of asymptomatic gene carriers of transthyretin familial amyloid polyneuropathy. Muscle & Nerve. 2016; 54: 353\u2013360.","DOI":"10.1002\/mus.25210"},{"key":"ref92","doi-asserted-by":"publisher","unstructured":"Gonzalez-Lopez E, Escobar-Lopez L, Obici L, Saturi G, Bezard M, Saith SE, et al. Prognosis of Transthyretin Cardiac Amyloidosis Without Heart Failure Symptoms. JACC. CardioOncology. 2022; 4: 442\u2013454.","DOI":"10.1016\/j.jaccao.2022.07.007"},{"key":"ref93","doi-asserted-by":"publisher","unstructured":"Soman P, Garcia-Pavia P, Gillmore JD, Adams D, Conceicao I, Coelho T, et al. Rationale & Design of ACT-EARLY, the Acoramidis Transthyretin Amyloidosis Prevention Trial: Early Detection Using Cardiac Radionuclide Imaging. Journal of Nuclear Cardiology. 2024; 38.","DOI":"10.1016\/j.nuclcard.2024.101948"},{"key":"ref94","doi-asserted-by":"publisher","unstructured":"R\u00edos-Tamayo R, Krsnik I, G\u00f3mez-Bueno M, Garcia-Pavia P, Segovia-Cubero J, Huerta A, et al. AL Amyloidosis and Multiple Myeloma: A Complex Scenario in Which Cardiac Involvement Remains the Key Prognostic Factor. Life (Basel, Switzerland). 2023; 13: 1518.","DOI":"10.3390\/life13071518"},{"key":"ref95","doi-asserted-by":"publisher","unstructured":"Shetty M, Malhotra S. Novel Tracers for the Imaging of Cardiac Amyloidosis. Journal of Nuclear Medicine Technology. 2023; 51: 120\u2013124.","DOI":"10.2967\/jnmt.123.265568"},{"key":"ref96","doi-asserted-by":"publisher","unstructured":"Grogan M, Lopez-Jimenez F, Guthrie S, Kumar N, Langevin R, Lousada I, et al. Value of Artificial Intelligence for Enhancing Suspicion of Cardiac Amyloidosis Using Electrocardiography and Echocardiography: A Narrative Review. Journal of the American Heart Association. 2025; 14: e036533.","DOI":"10.1161\/JAHA.124.036533"},{"key":"ref97","doi-asserted-by":"publisher","unstructured":"Bumma N, Kahwash R, Parikh SV, Isfort M, Freimer M, Vallakati A, et al. Multidisciplinary amyloidosis care in the era of personalized medicine. Frontiers in Neurology. 2022; 13: 935936.","DOI":"10.3389\/fneur.2022.935936"},{"key":"ref98","doi-asserted-by":"publisher","unstructured":"Sohn HR, Song BG, Jeong SY, Hong SM, Jung HG, Jung HJ, et al. A Case of Cardiac Amyloidosis Initially Misdiagnosed as Syndrome X. Cardiology Research. 2011; 2: 181\u2013184.","DOI":"10.4021\/cr67w"},{"key":"ref99","doi-asserted-by":"publisher","unstructured":"George A, McClements B. Cardiac amyloidosis presenting as recurrent acute coronary syndrome with unobstructed coronary arteries: Case report. Indian Heart Journal. 2015; 67: 570\u2013573.","DOI":"10.1016\/j.ihj.2015.08.029"},{"key":"ref100","doi-asserted-by":"publisher","unstructured":"Taiwo AA, Alapati L, Movahed A. Cardiac amyloidosis: A case report and review of literature. World Journal of Clinical Cases. 2019; 7: 742\u2013752.","DOI":"10.12998\/wjcc.v7.i6.742"},{"key":"ref101","doi-asserted-by":"publisher","unstructured":"De Michieli L, De Gaspari M, Sinigiani G, Lupi A, Vedovelli L, Salvalaggio A, et al. Chest pain in cardiac amyloidosis: occurrence, causes and prognostic significance. International Journal of Cardiology. 2023; 389: 131204.","DOI":"10.1016\/j.ijcard.2023.131204"},{"key":"ref102","doi-asserted-by":"publisher","unstructured":"Mathew V, Olson LJ, Gertz MA, Hayes DL. Symptomatic conduction system disease in cardiac amyloidosis. The American Journal of Cardiology. 1997; 80: 1491\u20131492.","DOI":"10.1016\/s0002-9149(97)82785-3"},{"key":"ref103","doi-asserted-by":"publisher","unstructured":"Longhi S, Quarta CC, Milandri A, Lorenzini M, Gagliardi C, Manuzzi L, et al. Atrial fibrillation in amyloidotic cardiomyopathy: prevalence, incidence, risk factors and prognostic role. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis. 2015; 22: 147\u2013155.","DOI":"10.3109\/13506129.2015.1028616"},{"key":"ref104","unstructured":"Boufidou A, Mantziari L, Paraskevaidis S, Karvounis H, Nenopoulou E, Manthou ME, et al. An interesting case of cardiac amyloidosis initially diagnosed as hypertrophic cardiomyopathy. Hellenic Journal of Cardiology: HJC = Hellenike Kardiologike Epitheorese. 2010; 51: 552\u2013557."},{"key":"ref105","doi-asserted-by":"publisher","unstructured":"Argir\u00f2 A, Silverii MV, Burgisser C, Fattirolli F, Baldasseroni S, di Mario C, et al. Serial Changes in Cardiopulmonary Exercise Testing Parameters in Untreated Patients With Transthyretin Cardiac Amyloidosis. The Canadian Journal of Cardiology. 2024; 40: 364\u2013369.","DOI":"10.1016\/j.cjca.2023.09.028"},{"key":"ref106","doi-asserted-by":"publisher","unstructured":"Zhang D, Makhni MC, Kang JD, Blazar P. Orthopaedic Manifestations of Amyloidosis. The Journal of the American Academy of Orthopaedic Surgeons. 2021; 29: e488\u2013e496.","DOI":"10.5435\/JAAOS-D-20-01146"},{"key":"ref107","doi-asserted-by":"publisher","unstructured":"Zhang KW, Vallabhaneni S, Alvarez-Cardona JA, Krone RJ, Mitchell JD, Lenihan DJ. Cardiac Amyloidosis for the Primary Care Provider: A Practical Review to Promote Earlier Recognition of Disease. The American Journal of Medicine. 2021; 134: 587\u2013595.","DOI":"10.1016\/j.amjmed.2020.11.031"},{"key":"ref108","doi-asserted-by":"publisher","unstructured":"Cheng RK, Maurer MS. Recognition and Implications of Undiagnosed Cardiac Amyloid Patients in HFpEF Trials. JACC. Heart Failure. 2021; 9: 803\u2013806.","DOI":"10.1016\/j.jchf.2021.07.005"},{"key":"ref109","doi-asserted-by":"publisher","unstructured":"Fathala A. Incidentally detected cardiac amyloidosis on 99mTc-MDP bone scintigraphy. Radiology Case Reports. 2020; 15: 705\u2013708.","DOI":"10.1016\/j.radcr.2020.03.010"},{"key":"ref110","doi-asserted-by":"publisher","unstructured":"Kazi DS, Bellows BK, Baron SJ, Shen C, Cohen DJ, Spertus JA, et al. Cost-Effectiveness of Tafamidis Therapy for Transthyretin Amyloid Cardiomyopathy. Circulation. 2020; 141: 1214\u20131224.","DOI":"10.1161\/CIRCULATIONAHA.119.045093"},{"key":"ref111","doi-asserted-by":"publisher","unstructured":"Lau ATC, DiDomenico RJ, Kim K. Cost-effectiveness of systematic screening and treatment of transthyretin amyloid cardiomyopathy (ATTR-CM) in patients with heart failure with preserved ejection fraction (HFpEF) in United States. International Journal of Cardiology. 2024; 398: 131598.","DOI":"10.1016\/j.ijcard.2023.131598"},{"key":"ref112","doi-asserted-by":"publisher","unstructured":"Ge Y, Pandya A, Cuddy SAM, Singh A, Singh A, Dorbala S. Modeling the Cost and Health Impacts of Diagnostic Strategies in Patients with Suspected Transthyretin Cardiac Amyloidosis. Journal of the American Heart Association. 2022; 11: e026308.","DOI":"10.1161\/JAHA.122.026308"}],"container-title":["Reviews in Cardiovascular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.imrpress.com\/journal\/RCM\/26\/10\/10.31083\/RCM42514","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T12:38:42Z","timestamp":1762519122000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.imrpress.com\/journal\/RCM\/26\/10\/10.31083\/RCM42514"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,20]]},"references-count":112,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025]]}},"alternative-id":["S1530-6550(25)01958-1"],"URL":"https:\/\/doi.org\/10.31083\/rcm42514","relation":{},"ISSN":["1530-6550","2153-8174"],"issn-type":[{"value":"1530-6550","type":"print"},{"value":"2153-8174","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,20]]},"article-number":"42514"}}